CXCR2 and prostate carcinoma: CXCR2 antagonists have been evaluated in preclinical and clinical studies to block the interaction between CXCR2 and its ligands, which can influence the interaction between cancer cells and the tumor microenvironment in prostate cancer [19,20,21].